News Column

iBio Amends Commercial Collaboration Deal with Bio-Manguinhos and Fraunhofer

June 20, 2014

iBio amended its multiproduct license and collaboration agreement with Brazil's Bio-Manguinhos/Fiocruz and the Fraunhofer USA Center for Molecular Biotechnology to enable expansion of joint work on an iBioLaunch-produced recombinant yellow fever vaccine and other products.

Yellow fever vaccine candidates based on iBio's proprietary technology, including virus-like particles (VLPs) and traditional antigen formulations, have been highly successful in rodent virus- challenge studies. Additional tasks to be performed include non- human primate studies, the completion of IND-enabling tests, and the establishment of a commercial technology transfer program to enable Bio-Manguinhos to produce a recombinant iBioLaunch-based yellow fever vaccine in the new facility designed for that purpose that the Brazilian government has committed to build in northern Brazil.

Bio-Manguinhos/Fiocruz, a producer of yellow fever vaccines for worldwide use, is recognized internationally as a manufacturer of immunobiologicals for public health needs. Earlier this year, Sanofi Pasteur announced a potential yellow fever vaccine shortage for travelers due to a production problem with its own chicken egg- produced vaccine product.

Robert Erwin, iBio's president, commented: "The objective of our collaborative yellow fever vaccine development program is to enable Bio-Manguinhos to replace the current vaccine it produces in chicken eggs from a live, attenuated strain of the yellow fever virus, with a safe, low-cost, scalable recombinant vaccine produced in green plants with iBioLaunch technology."

iBio uses its proprietary technology for its own product portfolio

More information:


((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Manufacturing Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters